title: Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study.
abstract: OBJECTIVE
  To compare the efficacy and safety of 2 doses of botulinum toxin type A in the treatment of dermatochalasis.
  
  
  METHODS
  Forty patients with mild to moderate dermatochalasis were randomly assigned to receive 1 of 2 doses of botulinum toxin type A in the lateral infrabrow--4 U/brow or 6 U/brow--and followed up for 20 weeks.
  
  
  RESULTS
  Investigator assessment showed the proportion of responders (> or = 1 grade improvement in severity of dermatochalasis on a scale of none, mild, moderate, or severe) at week 2 was 32% with 4 U and 47% with 6 U. Compared with the lower dose group, the higher dose group also reported a greater degree of improvement, significantly higher ratings for feelings of attractiveness and feelings of satisfaction with appearance, and a higher incidence of satisfaction.
  
  
  CONCLUSIONS
  Single-site injection of botulinum toxin type A in the lateral infrabrow can offer effective treatment for mild to moderate upper eyelid dermatochalasis.
authors.affiliation: Department of Dermatology, University of Colorado, Englewood, CO, USA. denverskindoc@yahoo.com
authors.forename: Joel L
authors.initials: JL
authors.lastname: Cohen
authors.forename: Steven H
authors.initials: SH
authors.lastname: Dayan
mesh_terms: D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005141:Eyelid Diseases / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009468:Neuromuscular Diseases; D018579:Patient Selection; D016896:Treatment Outcome
chemical_list: D019274:Botulinum Toxins, Type A